Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Granite Bio has secured $100m in funding for its new antibody treatments that target several autoimmune diseases.

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

To meet growing demands amid an increasingly challenging industry landscape, a critical decision for a CRO is to ensure ...

The FDA has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal antibody, penpulimab ...